ArticleVeterinary research communications2026
Curcumin shows promise as an adjunct in changing β-lactam susceptibility status of canine multidrug-resistant Staphylococcus pseudintermedius: an in vitro study.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methicillin-resistant Staphylococcus pseudintermedius (MRSP) has become increasingly widespread in veterinary medicine, with a reported prevalence of up to 40.5% in dogs with pyoderma. Previous studies have shown that curcumin derived from turmeric (Curcuma longa L.) exhibits a synergistic effect when combined with β-lactam antibiotics, fluoroquinolones, tetracyclines, or vancomycin against strains of Staphylococcus aureus, including both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) isolates. Thus, the purpose of this study was to determine whether curcumin (500 µg/mL), in combination with oxacillin, amoxicillin-clavulanate, clindamycin, or doxycycline, could improve the susceptibility status of each antibiotic against multidrug-resistant Staphylococcus pseudintermedius (MDR-SP). Clinical isolates collected from dogs with MDR-SP pyoderma were tested against each antibiotic at their respective Clinical and Laboratory Standards Institute resistant, intermediate, and susceptible concentrations, in the presence or absence of curcumin. An ATCC methicillin-susceptible S. pseudintermedius reference strain (ATCC 49444) was included as an internal quality control. Exact McNemar test was used to assess paired isolate-level comparisons and a value of p < 0.05 was considered significant. A significant shift toward susceptibility was observed when curcumin was combined with oxacillin at the resistant (p = 0.001) and the susceptible (p < 0.0001) concentrations and with amoxicillin-clavulanate at the resistant (p = 0.002) and intermediate (p = 0.0078) concentrations. Amoxicillin-clavulanate at the susceptible concentration when combined with curcumin was not significant (p = 0.0625). Curcumin did not significantly alter the susceptibility status of clindamycin or doxycycline at any of the tested concentrations. Bactericidal concentrations were not observed at the tested concentrations. These results suggest that curcumin may potentiate the efficacy of select β-lactam antibiotics against MDR-SP, supporting curcumin as a potential β-lactam adjuvant against MDR-SP in vitro and warranting further evaluation.
Indexed as
Identifiers
42126633What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.